ClinicalTrials.gg
CompletedNCT05291520SPANUpdated Sep 19, 2024Results posted

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

A Phase 1 interventional study of VH3810109 and rHuPH20 in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
169th of 210
24 · median 82
Started
2022
with 5 others
Phase 1
83 of 266
9 open now
Registered
226th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 169th largest by enrollment of the 210 interventional ones that give a count, is one of 6 that started in 2022, is one of 83 in phase 1, and was the 226th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

An open-label, two part study to assess the safety, tolerability, and PK of VH3810109 in healthy adult participants. Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20 and will be followed up for 24 weeks.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • VH3810109
  • GSK3810109
  • HIV
  • Human Monoclonal Antibody
  • rHuPH20
  • Pharmacokinetics
  • Safety
  • Tolerability
  • N6LS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and without history of any of the conditions listed in the exclusion criteria.
  • Participants having body weight of ≥50 kilogram (kg) and \<100 kg
  • Participants having a clinical laboratory profile within the normal range or must have results that do not show abnormalities, as judged by the investigator at screening.
  • use by men or women participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Participants who are female at birth are eligible to participate if at least one of the following conditions applies:

Not pregnant or breastfeeding and at least one of the following conditions applies:

Is not a participant of (POCBP) or Is a POCBP and agree to use an acceptable contraceptive method as described in Section 10.4 from 3 weeks prior to the start of this study and during the study. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.

A POCBP must have a negative highly sensitive serum pregnancy test on Day -1, prior to the first dose of study intervention All participants in the study should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom).

The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.

  • Capable of giving written .

Exclusion criteria

Exclusion Criteria:

  • Hypertension that is not well controlled.
  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • Positive (HIV) antibody test.
  • Positive test result for SARS-CoV-2.
  • Evidence of (HB) virus infection at screening or within 3 months prior to first dose of study intervention Participants positive for Hepatitis B antigen (HBsAg) are excluded. Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for Hepatitis B virus (HBV) DNA are excluded
  • Any history of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis within the 2 years prior to enrollment that has a reasonable risk of recurrence during the study.
  • The participant has an underlying skin disease or disorder (i.e., infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria) or tattoos that would interfere with assessment of injection sites.
  • History of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
  • multiple or severe drug allergies, intolerance to topical , or severe post-treatment reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A, dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
  • Exposure to an experimental drug, human blood product, or vaccine (which does not have emergency, conditional, or standard market authorization) within 28 days prior to the first dose of study treatment OR plans to receive during the study.
  • Prior receipt of licensed or Monoclonal antibody (Mab).
  • Receipt of any investigational study agent within 28 days prior to first dose of study treatment
  • Prior exposure to VH3810109 or rHuPH20 in this or another clinical study.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 milliliter (mL) within 56 days.
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • ≥1.5 times the (ULN).
  • Total ≥1.5 times the ULN (isolated total bilirubin >1.5×ULN is acceptable if total bilirubin is fractionated and direct bilirubin \<35%).
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • interval Fridericia's formula (QTcF)>450 millisecond (msec) for males and QTcF >470 msec for females.
  • The participant has a tattoo or other dermatological condition overlying potential injection sites that may interfere with interpretation of ISRs or administration of VH3810109.
  • Grade 4 laboratory abnormalities.
  • Any other chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the subject including (but not limited to): diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of drug or alcohol abuse, asthma, disease, psychiatric disorders, heart disease, or cancer.
  • Known hypersensitivity to hyaluronidase or any of the in ENHANZ Drug Product (EDP)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]

    Participants in this group received a single subcutaneous (SC) dose of VH3810109 20 mg/kg co-administered with rHuPH20 at Day 1 and were followed up to 24 weeks.

    Biological: VH3810109 · Biological: rHuPH20

  • Experimental
    Part 2 Group: VH3810109 60 mg/kg [IV]

    Participants in this group received a single intravenous (IV) dose of VH3810109 60 mg/kg at Day 1 and were followed up to 24 weeks.

    Biological: VH3810109

  • Experimental
    Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]

    Participants in this group received a single subcutaneous (SC) dose of VH3810109 3000 mg co-administered with rHuPH20 at Day 1 and were followed up to 24 weeks.

    Biological: VH3810109 · Biological: rHuPH20

Interventions

  • BiologicalVH3810109

    VH3810109 was administered.

  • BiologicalrHuPH20

    rHuPH20 was administered.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.

    Time frame: Up to Week 24

  2. Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)

    An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.

    Time frame: Up to Week 24

  3. Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)

    ISRs were recorded via ISR diaries and managed through investigator assessment. The participants who experienced any injection site reaction were reported.

    Time frame: Up to 7 days post-dose

  4. Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)

    Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.

    Time frame: Up to Week 24

  5. Number of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.

    Time frame: Up to Week 24

  6. Number of Participants With SAEs Following IV Administration of VH3810109 (Part 2)

    An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.

    Time frame: Up to Week 24

  7. Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)

    Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.

    Time frame: Up to Week 24

Secondary outcomes

  1. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109

    Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis of VH3810109.

    Time frame: Up to Week 24

  2. AUC From Time Zero to Time t (AUC[0-t]) of VH3810109

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

    Time frame: Up to Week 24

  3. Maximum Observed Concentration (Cmax) of VH3810109

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

    Time frame: Up to Week 24

  4. Time of Maximum Observed Concentration (Tmax) of VH3810109

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

    Time frame: Up to Week 24

  5. Apparent Terminal Phase Half-life (t1/2) of VH3810109

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

    Time frame: Up to Week 24

  6. Score Recorded for "Acceptance of ISRs", Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)

    The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

    Time frame: At Day 2 and Day 7

  7. Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)

    The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defined as following: 1=not at all bothered, 2=a little bothered, 3=moderately bothered, 4=very bothered, 5=extremely bothered; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

    Time frame: At Day 2 and Day 7

  8. Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)

    The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defind as following: 1=totaly acceptable, 2=very acceptable, 3=moderately acceptable, 4=a little acceptable, 5=not at all acceptable; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

    Time frame: At Day 2 and Day 7

  9. Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)

    Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).

    Time frame: At Day 1, Day 2 and Day 7

  10. Scores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)

    Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).

    Time frame: At Day 1, Day 2 and Day 7

  11. Number of ISRs Events Overall and by Grade (Part 1 and 3)

    ISRs were recorded via ISR diaries and managed through investigator assessment. Severity of injection site reactions was analyzed using DAIDS AE Grading Table. The severity was categorized into grades as following: Grade 1 (mild): causing no or minimal interference with usual social and functional activities, Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated, Grade 5 (death). Higher grade indicates more severe condition.

    Time frame: Up to day 14

  12. The Overall Duration of ISRs, Expressed in Days

    ISRs will be recorded via ISR diaries and managed through investigator assessment.

    Time frame: From Day 1 up to Day 14

  13. Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

    Time frame: From Baseline (Day -1) up to Week 24

  14. Change From Baseline in Hematocrit

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

    Time frame: From Baseline (Day -1) up to Week 24

  15. Change From Baseline in Hemoglobin, Albumin and Total Protein

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

    Time frame: From Baseline (Day -1) up to Week 24

  16. Change From Baseline in Red Blood Cell Count (RBC)

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

    Time frame: From Baseline (Day -1) up to Week 24

  17. Change From Baseline in Mean Corpuscle Volume (MCV)

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

    Time frame: From Baseline (Day -1) up to Week 24

  18. Change From Baseline in Mean Corpuscle Hemoglobin (MCH)

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

    Time frame: From Baseline (Day -1) up to Week 24

  19. Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

    Time frame: From Baseline (Day -1) up to Week 24

  20. Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

    Time frame: From Baseline (Day -1) up to Week 24

  21. Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

    Time frame: From Baseline (Day -1) up to Week 24

  22. Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline

    Urine samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109. At baseline and post-baseline, worst case urinalysis data was determined by comparing the resulted values of the urinalysis for each participant to the normal rage. This endpoint evaluates the changes from baseline for the worst case urinalysis.

    Time frame: Day 14 compared with baseline (Day -1)

  23. Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)

    ECG values were collected as assessed by protocol, at the indicated time points.

    Time frame: From Baseline (Day -1) up to Week 24

  24. Change From Baseline in Temperature

    Temperature was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

    Time frame: From Baseline (Day -1) up to Week 24

  25. Change From Baseline in Pulse Rate

    Pulse rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

    Time frame: From Baseline (Day -1) up to Week 24

  26. Change From Baseline in Respiratory Rate

    Respiratory rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

    Time frame: From Baseline (Day -1) up to Week 24

  27. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Blood pressure was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

    Time frame: From Baseline (Day -1) up to Week 24

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestonePart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Started888
Completed887
Not completed001
Withdrew: Lost to follow-up001

Outcome measures

PrimaryNumber of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)
ParticipantsPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)78
PrimaryNumber of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)

An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)
ParticipantsPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)00
PrimaryNumber of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)

ISRs were recorded via ISR diaries and managed through investigator assessment. The participants who experienced any injection site reaction were reported.

Time frame:
Up to 7 days post-dose
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)
ParticipantsPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)78
PrimaryNumber of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)

Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)
ParticipantsPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
ALT, Grade 200
ALT, Grade 300
ALT, Grade 400
AST, Grade 200
AST, Grade 300
AST, Grade 400
PrimaryNumber of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2)
ParticipantsPart 2 Group: VH3810109 60 mg/kg [IV]
Number of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2)0
PrimaryNumber of Participants With SAEs Following IV Administration of VH3810109 (Part 2)

An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With SAEs Following IV Administration of VH3810109 (Part 2)
ParticipantsPart 2 Group: VH3810109 60 mg/kg [IV]
Number of Participants With SAEs Following IV Administration of VH3810109 (Part 2)0
PrimaryNumber of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)

Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)
ParticipantsPart 2 Group: VH3810109 60 mg/kg [IV]
ALT, Grade 20
ALT, Grade 30
ALT, Grade 40
AST, Grade 20
AST, Grade 30
AST, Grade 40
SecondaryArea Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109

Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis of VH3810109.

Time frame:
Up to Week 24
Reported as:
Mean · Day*microgram/mililitre (day*μg/mL)
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109
Day*microgram/mililitre (day*μg/mL)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH38101097587 (4789 to 10380)31560 (27620 to 35490)12840 (8883 to 16800)
SecondaryAUC From Time Zero to Time t (AUC[0-t]) of VH3810109

Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

Time frame:
Up to Week 24
Reported as:
Mean · day*μg/mL
AUC From Time Zero to Time t (AUC[0-t]) of VH3810109
day*μg/mLPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
AUC From Time Zero to Time t (AUC[0-t]) of VH38101096996 (4512 to 9479)29160 (25550 to 32770)11590 (7819 to 15360)
SecondaryMaximum Observed Concentration (Cmax) of VH3810109

Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

Time frame:
Up to Week 24
Reported as:
Mean · μg/mL
Maximum Observed Concentration (Cmax) of VH3810109
μg/mLPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Maximum Observed Concentration (Cmax) of VH3810109148.2 (117.3 to 179.1)1864 (1620 to 2107)321.1 (201.6 to 440.6)
SecondaryTime of Maximum Observed Concentration (Tmax) of VH3810109

Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

Time frame:
Up to Week 24
Reported as:
Mean · Days
Time of Maximum Observed Concentration (Tmax) of VH3810109
DaysPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Time of Maximum Observed Concentration (Tmax) of VH38101094.503 (1.472 to 7.535)0.046 (0.045 to 0.047)2.882 (2.586 to 3.178)
SecondaryApparent Terminal Phase Half-life (t1/2) of VH3810109

Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

Time frame:
Up to Week 24
Reported as:
Mean · Days
Apparent Terminal Phase Half-life (t1/2) of VH3810109
DaysPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Apparent Terminal Phase Half-life (t1/2) of VH381010938.17 (23.41 to 52.93)46.97 (40.86 to 53.09)44.95 (34.14 to 55.76)
SecondaryScore Recorded for "Acceptance of ISRs", Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)

The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

Time frame:
At Day 2 and Day 7
Reported as:
Mean · Scores on a scale
Score Recorded for "Acceptance of ISRs", Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)
Scores on a scalePart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Acceptance of ISRs, Day 21.44 ± 1.0501.44 ± 0.496
Acceptance of ISRs, Day 71.44 ± 0.7291.50 ± 0.802
SecondaryNumber of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)

The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defined as following: 1=not at all bothered, 2=a little bothered, 3=moderately bothered, 4=very bothered, 5=extremely bothered; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

Time frame:
At Day 2 and Day 7
Reported as:
Count of participants · Participants
Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)
ParticipantsPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Not at all bothered by pain, Day 266
A little bothered by pain, Day 222
Moderately bothered by pain, Day 200
Very bothered by pain, Day 200
Extremely bothered by pain, Day 200
Not at all bothered by pain, Day 755
A little bothered by pain, Day 733
Moderately bothered by pain, Day 700
Very bothered by pain, Day 700
Extremely bothered by pain, Day 700
SecondaryNumber of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)

The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defind as following: 1=totaly acceptable, 2=very acceptable, 3=moderately acceptable, 4=a little acceptable, 5=not at all acceptable; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

Time frame:
At Day 2 and Day 7
Reported as:
Count of participants · Participants
Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)
ParticipantsPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Totally acceptable local reactions, Day 276
Very acceptable local reactions, Day 201
Moderately acceptable local reactions, Day 201
A little acceptable local reactions, Day 210
Not at all acceptable local reactions, Day 200
Totally acceptable local reactions, Day 756
Very acceptable local reactions, Day 721
Moderately acceptable local reactions, Day 711
A little acceptable local reactions, Day 700
Not at all acceptable local reactions, Day 700
Totally acceptable pain, Day 264
Very acceptable pain, Day 214
Moderately acceptable pain, Day 200
A little acceptable pain, Day 210
Not at all acceptable pain, Day 200
Totally acceptable pain, Day 765
Very acceptable pain, Day 711
Moderately acceptable pain, Day 712
A little acceptable pain, Day 700
Not at all acceptable pain, Day 700
SecondaryScore Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)

Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).

Time frame:
At Day 1, Day 2 and Day 7
Reported as:
Mean · Scores on a scale
Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)
Scores on a scalePart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Day 13.63 ± 2.3262.75 ± 2.550
Day 23.63 ± 2.6150.63 ± 0.744
Day 73.63 ± 2.9250.38 ± 0.744
SecondaryScores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)

Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).

Time frame:
At Day 1, Day 2 and Day 7
Reported as:
Mean · Scores on a scale
Scores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)
Scores on a scalePart 2 Group: VH3810109 60 mg/kg [IV]
Day 10.50 ± 1.069
Day 20.88 ± 1.642
Day 70.50 ± 1.414
SecondaryNumber of ISRs Events Overall and by Grade (Part 1 and 3)

ISRs were recorded via ISR diaries and managed through investigator assessment. Severity of injection site reactions was analyzed using DAIDS AE Grading Table. The severity was categorized into grades as following: Grade 1 (mild): causing no or minimal interference with usual social and functional activities, Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated, Grade 5 (death). Higher grade indicates more severe condition.

Time frame:
Up to day 14
Reported as:
Count of units · Number of events
Number of ISRs Events Overall and by Grade (Part 1 and 3)
Number of eventsPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Overall ISRs1418
Grade 1 ISRs26
Grade 2 ISRs52
Grade 3 ISRs710
Grade 4 ISRs00
Grade 5 ISRs00
SecondaryThe Overall Duration of ISRs, Expressed in Days

ISRs will be recorded via ISR diaries and managed through investigator assessment.

Time frame:
From Day 1 up to Day 14
Reported as:
Mean · Days
The Overall Duration of ISRs, Expressed in Days
DaysPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
The Overall Duration of ISRs, Expressed in Days2.9 ± 1.354.6 ± 6.29
SecondaryChange From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
10^9 cells/LPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Basophils, at Baseline0.033 ± 0.01390.035 ± 0.02070.044 ± 0.0106
Basophils, at Day 2-0.004 ± 0.00920.000 ± 0.0151-0.009 ± 0.0083
Basophils, at Day 3—0.005 ± 0.0152-0.009 ± 0.0113
Basophils, at Day 4—0.012 ± 0.0172-0.001 ± 0.0181
Basophils, at Day 70.008 ± 0.01280.003 ± 0.0128-0.005 ± 0.0107
Basophils, at Day 8—0.002 ± 0.0098—
Basophils, at Day 10—0.000 ± 0.0283—
Basophils, at Day 140.001 ± 0.00640.008 ± 0.01390.003 ± 0.0149
Basophils, at Week 40.003 ± 0.01390.004 ± 0.01410.000 ± 0.0185
Basophils, at Week 16-0.001 ± 0.00830.004 ± 0.0192-0.001 ± 0.0121
Basophils, at Week 240.000 ± 0.01510.001 ± 0.0259-0.013 ± 0.0160
Eosinophils, at Baseline0.121 ± 0.09570.098 ± 0.03330.145 ± 0.1370
Eosinophils, at Day 20.018 ± 0.08510.010 ± 0.01510.016 ± 0.0385
Eosinophils, at Day 3—0.017 ± 0.01210.010 ± 0.0513
Eosinophils, at Day 4—0.022 ± 0.01940.010 ± 0.0431
Eosinophils, at Day 70.016 ± 0.09640.000 ± 0.02930.016 ± 0.0619
Eosinophils, at Day 8—0.003 ± 0.0320—
Eosinophils, at Day 10—-0.010 ± 0.0424—
Eosinophils, at Day 140.059 ± 0.07180.011 ± 0.06240.025 ± 0.0444
Eosinophils, at Week 40.045 ± 0.06440.001 ± 0.0290-0.004 ± 0.0403
Eosinophils, at Week 160.059 ± 0.16670.053 ± 0.12690.013 ± 0.0605
Eosinophils, at Week 240.001 ± 0.10630.094 ± 0.1445-0.001 ± 0.0527
WBC, at Baseline5.13 ± 1.1616.31 ± 1.3656.50 ± 2.036
WBC, at Day 20.43 ± 0.696-0.31 ± 1.253-0.36 ± 0.980
WBC, at Day 3—0.13 ± 1.113-0.41 ± 1.089
WBC, at Day 4—0.32 ± 1.386-0.49 ± 1.360
WBC, at Day 70.11 ± 0.872-0.04 ± 1.171-0.25 ± 2.165
WBC, at Day 8—-0.05 ± 0.997—
WBC, at Day 10—-0.85 ± 0.071—
WBC, at Day 14-0.26 ± 0.809-0.38 ± 0.791-0.25 ± 0.994
WBC, at Week 4-0.03 ± 1.261-0.40 ± 0.857-0.48 ± 1.340
WBC, at Week 160.01 ± 0.892-0.63 ± 1.073-0.64 ± 1.162
WBC, at Week 24-0.46 ± 0.8830.40 ± 2.438-0.51 ± 0.540
Lymphocytes, at Baseline1.368 ± 0.26802.214 ± 0.55452.086 ± 0.4824
Lymphocytes, at Day 20.006 ± 0.1908-0.484 ± 0.3503-0.094 ± 0.2147
Lymphocytes, at Day 3—-0.175 ± 0.3459-0.135 ± 0.2727
Lymphocytes, at Day 4—-0.065 ± 0.3551-0.106 ± 0.3847
Lymphocytes, at Day 7-0.043 ± 0.1763-0.211 ± 0.3189-0.175 ± 0.3166
Lymphocytes, at Day 8—-0.193 ± 0.3462—
Lymphocytes, at Day 10—-0.475 ± 0.0778—
Lymphocytes, at Day 14-0.019 ± 0.1664-0.386 ± 0.3366-0.161 ± 0.3561
Lymphocytes, at Week 40.063 ± 0.1943-0.314 ± 0.2911-0.226 ± 0.2908
Lymphocytes, at Week 160.100 ± 0.2441-0.190 ± 0.2478-0.191 ± 0.3559
Lymphocytes, at Week 240.058 ± 0.3377-0.380 ± 0.3497-0.339 ± 0.4461
Monocytes, at Baseline0.396 ± 0.15560.461 ± 0.10380.485 ± 0.1488
Monocytes, at Day 20.091 ± 0.1037-0.048 ± 0.1159-0.008 ± 0.0587
Monocytes, at Day 3—0.040 ± 0.0639-0.013 ± 0.0886
Monocytes, at Day 4—0.080 ± 0.0957-0.006 ± 0.1034
Monocytes, at Day 70.049 ± 0.1185-0.021 ± 0.1572-0.013 ± 0.1413
Monocytes, at Day 8—0.008 ± 0.1019—
Monocytes, at Day 10—-0.110 ± 0.1131—
Monocytes, at Day 140.034 ± 0.1347-0.078 ± 0.1237-0.015 ± 0.1319
Monocytes, at Week 40.036 ± 0.1061-0.045 ± 0.1146-0.034 ± 0.1010
Monocytes, at Week 160.023 ± 0.0630-0.029 ± 0.12210.001 ± 0.0724
Monocytes, at Week 24-0.018 ± 0.10990.001 ± 0.1670-0.020 ± 0.0462
Neutrophils, at Baseline3.218 ± 0.91573.499 ± 0.97833.756 ± 1.6757
Neutrophils, at Day 20.315 ± 0.83330.214 ± 1.0869-0.263 ± 0.9093
Neutrophils, at Day 3—0.238 ± 0.9621-0.291 ± 0.9503
Neutrophils, at Day 4—0.262 ± 1.0730-0.398 ± 1.0114
Neutrophils, at Day 70.066 ± 0.81770.210 ± 0.9063-0.079 ± 1.8480
Neutrophils, at Day 8—0.160 ± 0.8802—
Neutrophils, at Day 10—-0.270 ± 0.3111—
Neutrophils, at Day 14-0.340 ± 0.75310.096 ± 0.8912-0.116 ± 0.7571
Neutrophils, at Week 4-0.160 ± 1.2887-0.036 ± 0.9269-0.233 ± 1.1531
Neutrophils, at Week 16-0.178 ± 0.6481-0.468 ± 0.9437-0.500 ± 0.9401
Neutrophils, at Week 24-0.535 ± 0.85110.691 ± 2.3541-0.160 ± 0.6340
Platelets, at Baseline256.3 ± 48.96301.9 ± 34.84289.5 ± 71.95
Platelets, at Day 26.6 ± 12.70-14.6 ± 12.951.0 ± 18.48
Platelets, at Day 3—3.2 ± 19.770.1 ± 19.63
Platelets, at Day 4—-4.2 ± 17.22-4.9 ± 20.16
Platelets, at Day 71.4 ± 13.650.0 ± 13.491.9 ± 23.46
Platelets, at Day 8—2.8 ± 12.14—
Platelets, at Day 10—-8.0 ± 19.80—
Platelets, at Day 1419.9 ± 32.891.0 ± 52.602.1 ± 40.86
Platelets, at Week 430.6 ± 87.1-3.5 ± 15.103.1 ± 31.31
Platelets, at Week 16-0.5 ± 19.346.6 ± 35.49-6.4 ± 31.43
Platelets, at Week 241.1 ± 27.5812.5 ± 37.14-2.3 ± 27.79
SecondaryChange From Baseline in Hematocrit

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit
Proportion of red blood cells in bloodPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Baseline0.3873 ± 0.045410.3928 ± 0.044150.4253 ± 0.04709
Day 20.0159 ± 0.022260.0005 ± 0.015130.0118 ± 0.01704
Day 3—0.0100 ± 0.026120.0066 ± 0.01502
Day 4—0.0003 ± 0.019920.0023 ± 0.01646
Day 70.0168 ± 0.016620.0043 ± 0.01521-0.0065 ± 0.01208
Day 8—0.0062 ± 0.01781—
Day 10—-0.0270 ± 0.01131—
Day 140.0118 ± 0.01426-0.0074 ± 0.01736-0.0056 ± 0.01420
Week 40.0016 ± 0.01672-0.0013 ± 0.01641-0.0069 ± 0.01605
Week 160.0196 ± 0.023030.0078 ± 0.02315-0.0106 ± 0.00759
Week 240.0119 ± 0.013890.0053 ± 0.02437-0.0076 ± 0.03243
SecondaryChange From Baseline in Hemoglobin, Albumin and Total Protein

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline in Hemoglobin, Albumin and Total Protein
Grams per liter (g/L)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Hemoglobin, at Baseline131.4 ± 16.78128.3 ± 15.83142.4 ± 15.67
Hemoglobin, at Day 25.8 ± 6.901.9 ± 4.613.9 ± 6.49
Hemoglobin, at Day 3—6.8 ± 6.794.3 ± 5.39
Hemoglobin, at Day 4—4.8 ± 7.193.9 ± 5.46
Hemoglobin, at Day 72.6 ± 6.352.9 ± 5.28-0.4 ± 4.37
Hemoglobin, at Day 8—3.3 ± 4.84—
Hemoglobin, at Day 10—-10.0 ± 4.24—
Hemoglobin, at Day 143.4 ± 4.78-0.8 ± 5.90-0.4 ± 4.47
Hemoglobin, at Week 41.0 ± 5.290.4 ± 6.55-1.4 ± 4.96
Hemoglobin, at Week 164.3 ± 7.235.3 ± 8.01-3.4 ± 4.12
Hemoglobin, at Week 240.4 ± 4.074.0 ± 7.54-1.4 ± 13.99
Albumin, at Baseline44.0 ± 3.0243.9 ± 3.0043.9 ± 3.44
Albumin, at Day 20.4 ± 2.07-2.4 ± 2.45-0.3 ± 1.83
Albumin, at Day 3—-0.3 ± 1.86-0.1 ± 1.73
Albumin, at Day 4—-0.8 ± 2.400.3 ± 1.58
Albumin, at Day 70.1 ± 2.80-1.9 ± 1.810.4 ± 2.00
Albumin, at Day 8—-1.7 ± 1.75—
Albumin, at Day 10—-5.5 ± 0.71—
Albumin, at Day 140.0 ± 2.00-1.0 ± 1.51-0.1 ± 1.89
Albumin, at Week 4-1.4 ± 2.56-0.1 ± 2.10-0.3 ± 2.43
Albumin, at Week 160.6 ± 1.770.8 ± 2.19-2.0 ± 2.16
Albumin, at Week 24-1.5 ± 2.14-0.3 ± 1.04-1.9 ± 2.48
Total Protein, at Baseline70.0 ± 3.8571.0 ± 3.6672.3 ± 4.40
Total Protein, at Day 20.6 ± 4.17-1.4 ± 4.17-1.5 ± 3.51
Total Protein, at Day 3—1.3 ± 3.93-1.9 ± 3.04
Total Protein, at Day 4—0.0 ± 4.430.6 ± 2.20
Total Protein, at Day 70.0 ± 4.57-2.8 ± 2.76-0.1 ± 3.52
Total Protein, at Day 8—2.76 ± 2.86—
Total Protein, at Day 10—-8.0 ± 0.00—
Total Protein, at Day 140.0 ± 4.14-1.6 ± 2.56-0.8 ± 2.71
Total Protein, at Week 4-0.6 ± 3.16-1.0 ± 3.38-1.9 ± 3.14
Total Protein, at Week 160.9 ± 2.421.0 ± 3.85-4.4 ± 3.87
Total Protein, at Week 24-3.4 ± 3.960.1 ± 2.17-2.7 ± 4.46
SecondaryChange From Baseline in Red Blood Cell Count (RBC)

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · Trillion cells/L (TI/L)
Change From Baseline in Red Blood Cell Count (RBC)
Trillion cells/L (TI/L)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Baseline4.518 ± 0.55184.523 ± 0.40144.889 ± 0.6362
Day 20.180 ± 0.26540.043 ± 0.17170.141 ± 0.2154
Day 3—0.163 ± 0.30640.079 ± 0.1890
Day 4—0.085 ± 0.22390.056 ± 0.2169
Day 70.155 ± 0.20670.084 ± 0.1584-0.074 ± 0.1429
Day 8—0.088 ± 0.1877—
Day 10—-0.315 ± 0.1626—
Day 140.130 ± 0.1646-0.088 ± 0.1940-0.064 ± 0.1686
Week 40.050 ± 0.1802-0.026 ± 0.1625-0.078 ± 0.1814
Week 160.186 ± 0.26120.124 ± 0.2212-0.164 ± 0.0752
Week 240.063 ± 0.14960.078 ± 0.2326-0.110 ± 0.3089
SecondaryChange From Baseline in Mean Corpuscle Volume (MCV)

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · cubic microns
Change From Baseline in Mean Corpuscle Volume (MCV)
cubic micronsPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Baseline85.78 ± 2.01386.89 ± 6.08187.28 ± 3.478
Day 20.14 ± 0.466-0.66 ± 0.478-0.03 ± 0.354
Day 3—-0.72 ± 0.492-0.03 ± 0.345
Day 4—-1.38 ± 0.542-0.41 ± 0.589
Day 70.84 ± 0.661-0.61 ± 0.562-0.10 ± 0.469
Day 8—-0.27 ± 0.674—
Day 10—0.05 ± 0.354—
Day 140.06 ± 0.7840.04 ± 0.7460.06 ± 0.623
Week 4-0.53 ± 1.2160.34 ± 1.125-0.03 ± 0.703
Week 160.76 ± 0.842-0.75 ± 2.5220.74 ± 1.078
Week 241.34 ± 1.983-0.41 ± 2.1070.40 ± 2.195
SecondaryChange From Baseline in Mean Corpuscle Hemoglobin (MCH)

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · picograms (pg)
Change From Baseline in Mean Corpuscle Hemoglobin (MCH)
picograms (pg)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Baseline29.05 ± 1.02828.33 ± 2.21329.26 ± 1.660
Day 20.20 ± 0.5530.21 ± 0.458-0.08 ± 0.345
Day 3—0.63 ± 0.8360.39 ± 0.290
Day 4—0.67 ± 0.4630.55 ± 0.678
Day 7-0.36 ± 0.3020.16 ± 0.3850.29 ± 0.536
Day 8—0.27 ± 0.480—
Day 10—-0.20 ± 0.141—
Day 14-0.06 ± 0.4750.44 ± 0.5240.33 ± 0.590
Week 4-0.09 ± 0.6080.39 ± 0.6170.16 ± 0.466
Week 16-0.21 ± 0.6130.39 ± 0.7790.24 ± 0.737
Week 24-0.39 ± 1.0510.39 ± 0.7160.31 ± 1.524
SecondaryChange From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · milligram per deciliter (mg/dL)
Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin
milligram per deciliter (mg/dL)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Glucose, at Baseline5.009778 ± 0.26497365.037533 ± 0.25824304.864064 ± 0.2032812
Glucose, at Day 2-0.006939 ± 0.23066960.256734 ± 0.58816470.145714 ± 0.2966207
Glucose, at Day 3—-0.018503 ± 0.29303110.201224 ± 0.3645321
Glucose, at Day 4—-0.027755 ± 0.2868315-0.006939 ± 0.2852734
Glucose, at Day 70.180408 ± 0.17237490.548161 ± 1.15315740.166530 ± 0.3408978
Glucose, at Day 8—-0.111020 ± 0.3330600—
Glucose, at Day 10—0.000000 ± 0.1570060—
Glucose, at Day 14-0.027755 ± 0.25866880.048571 ± 0.38849920.006939 ± 0.2790329
Glucose, at Week 40.027755 ± 0.3857275-0.124898 ± 0.28421060.215101 ± 0.5168587
Glucose, at Week 16-0.180408 ± 0.22548270.076326 ± 0.21383450.111020 ± 0.3376541
Glucose, at Week 24-0.249795 ± 0.3040408-0.208163 ± 0.35574690.237900 ± 0.3184202
Blood urea nitrogen, at Baseline3.83775 ± 0.7311344.19475 ± 1.3769814.73025 ± 1.594955
Blood urea nitrogen, at Day 21.21380 ± 0.6787030.39270 ± 0.9377620.27221 ± 1.307383
Blood urea nitrogen, at Day 3—0.67830 ± 0.6512680.16511 ± 1.369415
Blood urea nitrogen, at Day 4—0.82705 ± 0.9274900.15619 ± 1.726718
Blood urea nitrogen, at Day 70.30345 ± 1.0427470.58459 ± 1.250583-0.42840 ± 1.421995
Blood urea nitrogen, at Day 8—0.55930 ± 0.809900—
Blood urea nitrogen, at Day 10—0.35700 ± 0.000000—
Blood urea nitrogen, at Day 140.02678 ± 0.714446-0.33915 ± 1.192768-0.50873 ± 1.656633
Blood urea nitrogen, at Week 40.31684 ± 0.895135-0.16065 ± 0.695659-0.24098 ± 1.082288
Blood urea nitrogen, at Week 160.21420 ± 1.260309-0.41948 ± 0.8057110.03060 ± 1.359639
Blood urea nitrogen, at Week 240.32576 ± 1.0746380.26775 ± 1.474420-0.05610 ± 1.187055
Creatinine, at Baseline68.2890 ± 15.1850468.0680 ± 13.5638173.8140 ± 15.20157
Creatinine, at Day 21.4365 ± 8.05969-3.2045 ± 3.979752.3205 ± 9.02667
Creatinine, at Day 3—-0.7367 ± 6.160583.6465 ± 5.49905
Creatinine, at Day 4—-0.5893 ± 6.038870.8840 ± 7.94898
Creatinine, at Day 70.0000 ± 5.844722.4310 ± 6.711586.2985 ± 9.30077
Creatinine, at Day 8—-0.4420 ± 6.01510—
Creatinine, at Day 10—11.9340 ± 3.12541—
Creatinine, at Day 140.1105 ± 3.822360.6630 ± 6.491753.4255 ± 5.98510
Creatinine, at Week 42.9835 ± 7.055210.1105 ± 4.184852.7625 ± 6.78911
Creatinine, at Week 16-0.3315 ± 6.87895-0.7735 ± 7.983143.1571 ± 5.32501
Creatinine, at Week 242.0995 ± 4.25102-0.2210 ± 5.625745.6829 ± 7.60201
Direct Bilirubin, at Baseline2.0306 ± 0.495921.7741 ± 0.626212.1161 ± 1.04191
Direct Bilirubin, at Day 2-0.5771 ± 0.42811-0.2138 ± 0.45473-0.0214 ± 0.44250
Direct Bilirubin, at Day 3—-0.1425 ± 0.45134-0.1069 ± 0.43776
Direct Bilirubin, at Day 4—0.0285 ± 0.476560.1283 ± 0.58348
Direct Bilirubin, at Day 70.0000 ± 0.438360.0214 ± 0.42320-0.1283 ± 0.33893
Direct Bilirubin, at Day 8—0.1995 ± 0.53440—
Direct Bilirubin, at Day 10—-0.5130 ± 0.48366—
Direct Bilirubin, at Day 14-0.2351 ± 0.57763-0.3634 ± 0.46997-0.1710 ± 0.44778
Direct Bilirubin, at Week 4-0.5344 ± 0.622870.0000 ± 0.42872-0.1496 ± 0.50427
Direct Bilirubin, at Week 16-0.3206 ± 0.59544-0.2138 ± 0.52308-0.7817 ± 0.56591
Direct Bilirubin, at Week 24-0.3420 ± 0.49222-0.2565 ± 0.61993-0.3176 ± 0.36178
Total bilirubin, at Baseline9.7684 ± 3.9562310.4738 ± 3.2851212.5258 ± 7.47987
Total bilirubin, at Day 2-1.9879 ± 2.22382-1.1115 ± 3.086130.6413 ± 2.98813
Total bilirubin, at Day 3—-0.8550 ± 2.991280.4061 ± 3.48526
Total bilirubin, at Day 4—0.0570 ± 2.840182.0306 ± 4.64850
Total bilirubin, at Day 71.6031 ± 2.82603-0.2565 ± 3.16102-0.4703 ± 2.08181
Total bilirubin, at Day 8—0.9405 ± 3.54057—
Total bilirubin, at Day 10—-2.3085 ± 1.81373—
Total bilirubin, at Day 140.6199 ± 3.02728-2.4368 ± 2.07377-0.6199 ± 3.52222
Total bilirubin, at Week 4-1.7528 ± 3.77392-1.1115 ± 1.51851-0.3206 ± 3.67145
Total bilirubin, at Week 16-0.4061 ± 3.45758-1.5390 ± 2.90772-2.4917 ± 2.46196
Total bilirubin, at Week 240.0428 ± 2.98813-0.6840 ± 3.10368-1.6856 ± 2.63700
SecondaryChange From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · Millimole per liter (mmol/L)
Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide
Millimole per liter (mmol/L)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Calcium, at Baseline2.329706 ± 0.10495752.317231 ± 0.08050282.351538 ± 0.0931159
Calcium, at Day 2-0.015594 ± 0.1041067-0.003119 ± 0.0983979-0.003119 ± 0.0983979
Calcium, at Day 3—0.037425 ± 0.11017620.003119 ± 0.0759557
Calcium, at Day 4—0.008317 ± 0.11451660.040544 ± 0.0729700
Calcium, at Day 7-0.012475 ± 0.0533453-0.006238 ± 0.08301800.037425 ± 0.0442316
Calcium, at Day 8—-0.004158 ± 0.0639356—
Calcium, at Day 10—-0.112275 ± 0.0882116—
Calcium, at Day 140.009356 ± 0.0398698-0.034306 ± 0.0923367-0.009356 ± 0.0923367
Calcium, at Week 4-0.031188 ± 0.0739536-0.034306 ± 0.08532910.003119 ± 0.0826826
Calcium, at Week 16-0.015594 ± 0.08428050.018713 ± 0.0751464-0.064157 ± 0.0496021
Calcium, at Week 24-0.056138 ± 0.0861717-0.031188 ± 0.0371268-0.053464 ± 0.1002445
Carbon Dioxide, at Baseline29.4 ± 1.7727.8 ± 2.2528.6 ± 1.92
Carbon Dioxide, at Day 20.5 ± 1.410.6 ± 1.190.4 ± 1.41
Carbon Dioxide, at Day 3—1.5 ± 0.84-0.5 ± 0.93
Carbon Dioxide, at Day 4—1.3 ± 1.030.3 ± 1.28
Carbon Dioxide, at Day 7-0.3 ± 1.390.3 ± 1.280.3 ± 0.71
Carbon Dioxide, at Day 8—1.3 ± 1.03—
Carbon Dioxide, at Day 10—0.0 ± 1.41—
Carbon Dioxide, at Day 140.3 ± 0.890.5 ± 1.51-0.4 ± 1.41
Carbon Dioxide, at Week 41.5 ± 1.510.9 ± 1.640.0 ± 0.93
Carbon Dioxide, at Week 16-1.3 ± 1.280.3 ± 0.71-0.4 ± 0.98
Carbon Dioxide, at Week 24-0.5 ± 1.200.4 ± 1.510.3 ± 1.38
Chloride, at Baseline103.1 ± 1.81102.1 ± 2.59102.4 ± 2.20
Chloride, at Day 2-0.6 ± 2.450.0 ± 2.000.1 ± 2.42
Chloride, at Day 3—-1.2 ± 1.94-0.3 ± 2.49
Chloride, at Day 4—-1.5 ± 1.64-0.4 ± 2.39
Chloride, at Day 7-0.5 ± 1.070.1 ± 1.640.5 ± 2.14
Chloride, at Day 8—0.3 ± 1.75—
Chloride, at Day 10—5.5 ± 2.12—
Chloride, at Day 14-1.6 ± 1.771.0 ± 2.560.4 ± 2.13
Chloride, at Week 4-1.3 ± 2.381.1 ± 2.470.4 ± 1.06
Chloride, at Week 16-0.4 ± 2.131.5 ± 1.410.7 ± 1.80
Chloride, at Week 24-0.1 ± 2.360.6 ± 2.261.7 ± 2.21
Potassium, at Baseline4.36 ± 0.4844.14 ± 0.3424.29 ± 0.485
Potassium, at Day 20.09 ± 0.2420.16 ± 0.3250.10 ± 0.366
Potassium, at Day 3—0.13 ± 0.3720.14 ± 0.250
Potassium, at Day 4—0.00 ± 0.5440.13 ± 0.320
Potassium, at Day 7-0.30 ± 0.4210.29 ± 0.470-0.01 ± 0.340
Potassium, at Day 8—0.07 ± 0.207—
Potassium, at Day 10—0.45 ± 0.354—
Potassium, at Day 14-0.13 ± 0.3810.04 ± 0.5130.09 ± 0.458
Potassium, at Week 4-0.16 ± 0.3890.18 ± 0.183-0.01 ± 0.196
Potassium, at Week 16-0.38 ± 0.4130.11 ± 0.189-0.04 ± 0.382
Potassium, at Week 24-0.06 ± 0.245-0.03 ± 0.3540.01 ± 0.308
Sodium, at Baseline138.8 ± 1.39137.1 ± 2.23136.9 ± 2.53
Sodium, at Day 2-0.4 ± 2.13-0.4 ± 2.260.1 ± 2.30
Sodium, at Day 3—-0.8 ± 0.98-0.3 ± 1.49
Sodium, at Day 4—-1.3 ± 2.25-0.1 ± 1.89
Sodium, at Day 7-0.5 ± 1.770.5 ± 2.200.8 ± 1.98
Sodium, at Day 8—0.3 ± 1.51—
Sodium, at Day 10—4.5 ± 4.95—
Sodium, at Day 14-1.3 ± 1.391.0 ± 2.880.6 ± 1.85
Sodium, at Week 4-0.9 ± 2.171.0 ± 2.450.9 ± 1.64
Sodium, at Week 16-0.8 ± 1.581.0 ± 2.511.3 ± 1.60
Sodium, at Week 24-1.1 ± 2.530.1 ± 3.482.0 ± 2.24
SecondaryChange From Baseline in ALT, AST and Alkaline Phosphatase (ALP)

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · International Units per liter (IU/L)
Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)
International Units per liter (IU/L)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
ALT, at Baseline11.8 ± 2.7112.5 ± 4.0020.0 ± 8.09
ALT, at Day 20.6 ± 1.69-0.5 ± 1.31-1.8 ± 3.45
ALT, at Day 3—0.5 ± 1.52-1.1 ± 4.61
ALT, at Day 4—0.5 ± 2.43-0.8 ± 6.14
ALT, at Day 71.5 ± 2.830.5 ± 2.732.0 ± 7.91
ALT, at Day 8—0.8 ± 3.76—
ALT, at Day 10—-1.0 ± 1.41—
ALT, at Day 141.0 ± 1.410.6 ± 2.13-2.0 ± 5.81
ALT, at Week 44.3 ± 6.341.6 ± 3.66-1.9 ± 8.18
ALT, at Week 164.4 ± 2.721.4 ± 2.45-0.1 ± 7.06
ALT, at Week 242.0 ± 4.441.3 ± 5.70-1.3 ± 5.96
AST, at Baseline14.5 ± 2.3916.0 ± 2.9818.1 ± 2.64
AST, at Day 20.4 ± 2.001.4 ± 1.77-1.8 ± 3.06
AST, at Day 3—2.7 ± 1.63-0.6 ± 3.42
AST, at Day 4—1.8 ± 1.720.5 ± 3.66
AST, at Day 72.8 ± 2.820.8 ± 3.062.5 ± 3.74
AST, at Day 8—1.0 ± 3.03—
AST, at Day 10—-2.5 ± 0.71—
AST, at Day 141.9 ± 2.031.8 ± 2.76-0.9 ± 3.40
AST, at Week 43.0 ± 3.514.3 ± 8.960.0 ± 4.38
AST, at Week 162.9 ± 1.811.1 ± 3.140.4 ± 3.95
AST, at Week 242.0 ± 4.780.1 ± 2.47-0.7 ± 2.63
ALP, at Baseline54.6 ± 8.9955.9 ± 20.0057.1 ± 9.30
ALP, at Day 22.9 ± 3.830.6 ± 4.50-2.4 ± 4.44
ALP, at Day 3—4.7 ± 4.030.0 ± 4.81
ALP, at Day 4—4.0 ± 5.833.0 ± 3.89
ALP, at Day 74.6 ± 2.775.9 ± 4.054.9 ± 5.33
ALP, at Day 8—6.8 ± 5.04—
ALP, at Day 10—-1.5 ± 4.95—
ALP, at Day 147.6 ± 2.974.4 ± 4.172.8 ± 4.71
ALP, at Week 40.6 ± 6.507.9 ± 4.52-1.8 ± 2.76
ALP, at Week 164.8 ± 5.235.4 ± 5.421.0 ± 5.39
ALP, at Week 24-0.1 ± 5.173.3 ± 5.851.6 ± 4.89
SecondaryNumber of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline

Urine samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109. At baseline and post-baseline, worst case urinalysis data was determined by comparing the resulted values of the urinalysis for each participant to the normal rage. This endpoint evaluates the changes from baseline for the worst case urinalysis.

Time frame:
Day 14 compared with baseline (Day -1)
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline
ParticipantsPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Glucose100
Protein011
Leukocyte esterase011
SecondaryChange From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)

ECG values were collected as assessed by protocol, at the indicated time points.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · Miliseconds
Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)
MilisecondsPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
PR Interval, at Baseline161.375 ± 20.2762164.000 ± 16.6733164.875 ± 14.2872
PR Interval, at Day 1-4.000 ± 10.7157—0.500 ± 4.5145
PR Interval, at Day 2-0.208 ± 7.52971.917 ± 9.52823.500 ± 7.6677
PR Interval, at Day 31.083 ± 7.84933.000 ± 10.63543.667 ± 10.6845
PR Interval, at Day 44.625 ± 8.61790.875 ± 10.86563.000 ± 10.0775
PR Interval, at Day 71.458 ± 11.62236.167 ± 10.95162.625 ± 6.3507
PR Interval, at Day 8—5.875 ± 9.4330—
PR Interval, at Day 10—19.167 ± 8.7210—
PR Interval, at Week 49.542 ± 5.90384.250 ± 11.7700-2.250 ± 10.6231
PR Interval, at Week 244.583 ± 10.1164-0.958 ± 11.6571-1.905 ± 12.0872
QRS Interval, at Baseline92.875 ± 8.114190.750 ± 11.8291100.250 ± 12.1155
QRS Interval, at Day 10.875 ± 3.5587—-5.250 ± 6.8098
QRS Interval, at Day 2-2.292 ± 2.6693-0.458 ± 3.7116-3.708 ± 5.6833
QRS Interval, at Day 3-0.875 ± 2.3363-2.833 ± 6.2463-2.583 ± 3.6764
QRS Interval, at Day 41.458 ± 5.0895-1.875 ± 6.0708-4.458 ± 6.4855
QRS Interval, at Day 70.000 ± 5.1052-1.500 ± 6.8359-2.917 ± 6.3164
QRS Interval, at Day 8—-1.042 ± 4.6987—
QRS Interval, at Day 10—-4.333 ± 6.5997—
QRS Interval, at Week 40.708 ± 3.9337-0.958 ± 3.8398-4.708 ± 6.2372
QRS Interval, at Week 24-0.917 ± 4.5066-0.458 ± 4.4755-5.238 ± 6.4599
QT Interval, at Baseline378.875 ± 17.7719395.875 ± 19.1493380.375 ± 12.3513
QT Interval, at Day 10.708 ± 12.1713—-0.625 ± 8.6620
QT Interval, at Day 24.750 ± 12.129920.750 ± 18.968416.083 ± 13.6449
QT Interval, at Day 38.583 ± 18.265010.542 ± 27.05669.792 ± 12.7179
QT Interval, at Day 45.917 ± 22.16167.000 ± 27.07259.167 ± 18.5267
QT Interval, at Day 77.042 ± 20.797221.083 ± 21.47558.500 ± 13.6498
QT Interval, at Day 8—19.167 ± 20.0206—
QT Interval, at Day 10—31.667 ± 55.1543—
QT Interval, at Week 414.083 ± 18.061431.167 ± 17.002310.583 ± 13.7318
QT Interval, at Week 2415.125 ± 21.334813.167 ± 21.531815.952 ± 10.9771
QTcF Interval, at Baseline402.750 ± 10.5119419.375 ± 13.7523397.000 ± 14.8131
QTcF Interval, at Day 12.833 ± 10.0570—1.375 ± 9.1780
QTcF Interval, at Day 2-1.875 ± 9.29231.083 ± 15.44863.375 ± 11.7924
QTcF Interval, at Day 30.917 ± 9.5232-1.250 ± 14.90472.083 ± 8.6295
QTcF Interval, at Day 4-2.000 ± 15.0449-4.292 ± 18.32201.917 ± 9.0847
QTcF Interval, at Day 78.667 ± 22.83410.958 ± 9.67153.500 ± 11.9004
QTcF Interval, at Day 8—1.833 ± 14.8410—
QTcF Interval, at Day 10—0.667 ± 33.9411—
QTcF Interval, at Week 41.167 ± 10.63986.500 ± 8.85152.250 ± 8.4867
QTcF Interval, at Week 242.417 ± 10.59912.229 ± 14.87547.238 ± 5.6461
SecondaryChange From Baseline in Temperature

Temperature was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · Degrees Celcius
Change From Baseline in Temperature
Degrees CelciusPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Baseline36.54 ± 0.23336.79 ± 0.34436.49 ± 0.500
Day 2-0.10 ± 0.424-0.48 ± 0.437-0.14 ± 0.342
Day 3-0.23 ± 0.365-0.50 ± 0.475-0.25 ± 0.454
Day 4-0.03 ± 0.311-0.41 ± 0.569-0.20 ± 0.463
Day 7-0.05 ± 0.524-0.41 ± 0.622-0.04 ± 0.578
Day 8—-0.41 ± 0.599—
Day 10—-0.60 ± 0.566—
Day 14-0.13 ± 0.392-0.28 ± 0.492-0.28 ± 0.453
Day 21-0.11 ± 0.554-0.49 ± 0.352-0.04 ± 0.469
Week 4-0.21 ± 0.364-0.56 ± 0.534-0.09 ± 0.549
Week 8-0.28 ± 0.399-0.45 ± 0.535-0.20 ± 0.566
Week 12-0.23 ± 0.271-0.33 ± 0.607-0.28 ± 0.423
Week 16-0.34 ± 0.346-0.33 ± 0.575-0.69 ± 0.534
Week 20-0.17 ± 0.315-0.40 ± 0.414-0.19 ± 0.505
Week 24-0.19 ± 0.364-0.55 ± 0.6780.09 ± 0.367
SecondaryChange From Baseline in Pulse Rate

Pulse rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · Beats per minute (Beats/min)
Change From Baseline in Pulse Rate
Beats per minute (Beats/min)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Baseline73.9 ± 7.8571.1 ± 7.1675.9 ± 12.26
Day 2-4.4 ± 6.74-7.6 ± 8.28-13.8 ± 10.66
Day 3-7.6 ± 4.84-5.4 ± 9.01-12.1 ± 8.63
Day 4-6.4 ± 7.76-4.3 ± 8.75-8.1 ± 11.52
Day 7-1.4 ± 18.68-9.4 ± 6.95-8.4 ± 14.81
Day 8—-8.3 ± 5.78—
Day 10—-12.0 ± 7.07—
Day 14-4.5 ± 7.60-10.0 ± 6.72-11.4 ± 16.95
Day 21-3.1 ± 11.43-9.1 ± 5.06-11.0 ± 18.45
Week 4-7.3 ± 3.28-9.9 ± 7.34-13.4 ± 12.05
Week 8-3.9 ± 15.13-8.0 ± 8.09-8.3 ± 15.75
Week 12-4.8 ± 10.44-6.3 ± 7.44-9.8 ± 14.21
Week 16-11.1 ± 10.25-5.1 ± 8.61-10.6 ± 10.66
Week 20-9.0 ± 8.14-5.0 ± 5.01-12.4 ± 8.06
Week 24-10.5 ± 6.57-4.3 ± 4.80-15.3 ± 11.50
SecondaryChange From Baseline in Respiratory Rate

Respiratory rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · Breaths per minute (Breaths/min)
Change From Baseline in Respiratory Rate
Breaths per minute (Breaths/min)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Baseline15.5 ± 1.4115.8 ± 3.7713.8 ± 1.98
Day 1/4 Hours Postdose-1.4 ± 1.90-0.3 ± 3.452.0 ± 3.38
Day 1/8 Hours Postdose1.5 ± 2.56-2.3 ± 2.250.8 ± 3.85
Day 2-1.3 ± 3.20-2.0 ± 3.851.3 ± 2.12
Day 3-1.3 ± 2.12-1.5 ± 4.242.3 ± 2.71
Day 4-2.0 ± 2.14-1.5 ± 3.160.0 ± 2.62
Day 70.8 ± 4.77-2.8 ± 4.89-0.3 ± 2.92
Day 8—-0.8 ± 5.01—
Day 10—0.0 ± 5.66—
Day 14-1.5 ± 2.98-2.0 ± 3.38-1.3 ± 2.12
Day 21-1.3 ± 2.60-2.3 ± 2.921.0 ± 3.85
Week 41.3 ± 2.38-2.0 ± 4.411.0 ± 2.83
Week 81.0 ± 2.83-2.3 ± 4.591.3 ± 1.83
Week 12-1.0 ± 2.14-2.5 ± 3.341.5 ± 2.33
Week 16-2.0 ± 4.28-2.5 ± 5.423.1 ± 1.95
Week 20-0.9 ± 3.80-1.0 ± 3.211.1 ± 3.98
Week 24-3.3 ± 2.38-2.5 ± 1.770.3 ± 2.93
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Blood pressure was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercury (mmHg)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Systolic Blood Pressure, at Baseline112.8 ± 12.67106.3 ± 11.68114.4 ± 9.50
Systolic Blood Pressure, at Day 2-4.1 ± 12.243.5 ± 8.04-4.5 ± 7.19
Systolic Blood Pressure, at Day 3-2.9 ± 7.490.8 ± 5.99-4.5 ± 4.66
Systolic Blood Pressure, at Day 4-0.5 ± 9.200.3 ± 6.45-5.6 ± 6.23
Systolic Blood Pressure, at Day 72.1 ± 8.182.1 ± 6.033.6 ± 8.28
Systolic Blood Pressure, at Day 8—-2.4 ± 8.47—
Systolic Blood Pressure, at Day 10—4.5 ± 13.44—
Systolic Blood Pressure, at Day 142.4 ± 8.6811.3 ± 9.196.5 ± 10.38
Systolic Blood Pressure, at Day 215.4 ± 10.219.8 ± 13.367.8 ± 11.50
Systolic Blood Pressure, at Week 4-0.9 ± 8.549.5 ± 11.802.8 ± 7.85
Systolic Blood Pressure, at Week 89.0 ± 17.029.5 ± 14.435.6 ± 7.58
Systolic Blood Pressure, at Week 12-3.8 ± 4.894.5 ± 16.387.9 ± 11.54
Systolic Blood Pressure, at Week 164.6 ± 5.557.9 ± 11.08-0.3 ± 10.27
Systolic Blood Pressure, at Week 20-2.1 ± 14.282.1 ± 10.836.3 ± 7.83
Systolic Blood Pressure, at Week 242.0 ± 7.786.4 ± 10.07-0.1 ± 4.91
Diastolic Blood Pressure, at Baseline66.5 ± 9.7159.8 ± 6.4562.1 ± 5.59
Diastolic Blood Pressure, at Day 2-1.6 ± 5.483.4 ± 8.23-0.5 ± 6.89
Diastolic Blood Pressure, at Day 32.4 ± 4.871.1 ± 7.24-1.9 ± 5.51
Diastolic Blood Pressure, at Day 40.6 ± 6.05-2.3 ± 4.62-0.8 ± 4.86
Diastolic Blood Pressure, at Day 71.9 ± 8.32-1.6 ± 4.419.5 ± 9.78
Diastolic Blood Pressure, at Day 8—-1.8 ± 3.96—
Diastolic Blood Pressure, at Day 10—9.0 ± 8.49—
Diastolic Blood Pressure, at Day 141.6 ± 6.636.1 ± 3.726.1 ± 5.33
Diastolic Blood Pressure, at Day 212.8 ± 6.5010.6 ± 8.3712.9 ± 4.67
Diastolic Blood Pressure, at Week 42.1 ± 7.248.1 ± 6.407.6 ± 6.32
Diastolic Blood Pressure, at Week 86.4 ± 7.749.1 ± 3.447.6 ± 3.29
Diastolic Blood Pressure, at Week 120.5 ± 4.966.8 ± 7.1511.5 ± 7.78
Diastolic Blood Pressure, at Week 163.8 ± 3.159.1 ± 5.118.4 ± 6.73
Diastolic Blood Pressure, at Week 20-2.0 ± 7.096.3 ± 5.5513.6 ± 6.19
Diastolic Blood Pressure, at Week 241.5 ± 4.287.4 ± 6.5712.1 ± 7.49

Adverse events

Collected over SAEs, all cause mortality and non-SAEs were collected from Day 1 post-administration up to Week 24.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]0/8 (0%)0/8 (0%)8/8 (100%)
Part 2 Group: VH3810109 60 mg/kg [IV]0/8 (0%)0/8 (0%)1/8 (12.5%)
Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]0/8 (0%)0/8 (0%)8/8 (100%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPart 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]
Injection site erythemaGeneral disorders7/80/88/8
Upper respiratory tract infectionInfections and infestations2/80/81/8
Injection site painGeneral disorders1/80/82/8
Injection site bruisingGeneral disorders0/80/82/8
NasopharyngitisInfections and infestations0/80/82/8
HeadacheNervous system disorders1/80/80/8
Injection site pruritusGeneral disorders1/80/80/8
Muscle tightnessMusculoskeletal and connective tissue disorders1/81/80/8
ParaesthesiaNervous system disorders1/80/80/8
Post-traumatic painInjury, poisoning and procedural complications1/80/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]Total
Mean42.8 ± 7.7640.0 ± 14.4539.9 ± 10.5940.87 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]Total
Female57315
Male3159
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC]Part 2 Group: VH3810109 60 mg/kg [IV]Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC]Total
Asian2114
Black or African American1247
White54312
Multiple0101
08

Study locations

1 site
  • GSK Investigational Site
    Austin, Texas 78744, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Apr 2023, 13 months.

Results were first posted in Sep 2024, 1 year 5 months after primary completion.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 13 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Mar 22, 2022
StartActual
Feb 23, 2022
Primary completionActual
Apr 10, 2023
CompletionActual
Apr 10, 2023
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05291520
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Mar 22, 2022
Start date
Feb 23, 2022
Primary completion
Apr 10, 2023
Completion
Apr 10, 2023
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VH3810109

Start the discussion